ZYNE
Zynerba Pharmaceuticals Inc (ZYNE)
$1.15--
Key Stats
$1.05
Day's Range
$1.15
$0.8361
52-Week Range
$5.45
| Returns | |
| 1 month return | 20.1% |
| 3 month return | 43.35% |
| 1 year return | 77.71% |
| 5 year return | 77.32% |
Company Information
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.
| Organization | Zynerba Pharmaceuticals Inc |
| Employees | 26 |
| CEO | Armando Anido |
| Industry | Health Technology |
Analyst Recommendation
based on 12 analysts ratings
Buy
75%
Buy
25%
Hold
0%
Sell
Based on 12 Wall street analysts offering stock ratings for Zynerba Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 639.13%Current
$1.15
Target
$8.5
Recommendation Trend
Based on 12 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 9 | 9 | 10 |
| Hold | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 60.9M |
| Book Value | 1.76 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0 |
| Earnings Share | -0.95 |
| PEG Ratio | 0.0 |
| Wall Street Target Price | 6.95 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Sales (ttm) | 1152.69 |
| Price/Book (mrq) | 0.89 |
| Enterprise Value | -3999153 |
| Enterprise Value/Revenue | 397.61 |
| Enterprise Value/Ebitda | 0.11 |
Technicals
| Beta | 2.11 |
| 50 Day MA | 2.01 |
| 200 Day MA | 3.32 |
Institutional Holdings
ETF Managers Group, LLC
8.4%
Vanguard Group Inc
4.47%
Mirae Asset Global Investments (Korea) Co Ltd
2.86%
D. E. Shaw & Co LP
2.65%
BlackRock Inc
1.92%
Geode Capital Management, LLC
0.96%
